SCHEMBL9629050

SCHEMBL9629050

O=c1c2c(c3cccnc3n1-c1ccc(Cl)cc1)OCC2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.47
MAPT P10636 2/20 0.47
EP300 Q09472 1/20 0.41
CREBBP Q92793 1/20 0.41
KAT2A Q92830 1/20 0.41
KAT2B Q92831 1/20 0.41
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TP53 P04637 1/20 0.40
FEN1 P39748 1/20 0.39
PDE4B Q07343 8/20 0.39
PDE4D Q08499 6/20 0.39
PDE4A P27815 5/20 0.39
PDE4C Q08493 4/20 0.39
CYP2C19 P33261 3/20 0.38
MEN1 O00255 2/20 0.38
CYP1A2 P05177 2/20 0.38
KMT2A Q03164 2/20 0.38
THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9628857 0.93 HPGD (0.45) HPGDMAPTEP300CREBBPKAT2A
SCHEMBL9629732 0.92 HPGD (0.44) HPGDMAPTEP300CREBBPKAT2A
SCHEMBL9629666 0.91 MAPT (0.40) HPGDMAPTEP300CREBBPKAT2A
SCHEMBL9630002 0.89 FEN1 (0.50) MAPTKAT2BALDH1A1KDM4EL3MBTL1
SCHEMBL9629146 0.88 MAPT (0.49) HPGDMAPTALDH1A1KDM4EL3MBTL1
SCHEMBL9629850 0.88 HPGD (0.47) HPGDMAPTEP300CREBBPKAT2A
SCHEMBL9629742 0.88 CYP2C19 (0.47) HPGDMAPTKAT2BALDH1A1FEN1
SCHEMBL9630934 0.87 KAT2B (0.45) HPGDMAPTEP300CREBBPKAT2A
SCHEMBL10376979 0.87 PDE4B (0.42) HPGDMAPTKAT2BALDH1A1TP53
SCHEMBL9628888 0.85 PKM (0.47) MAPTKAT2BALDH1A1PDE4BPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0338010-B1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE SCHERING CORPORATION (US) 1992-02-05 EP claimed
EP-0127135-B1 FUSED TRICYCLIC DERIVATIVES OF NAPHTHYRIDINONE AND PYRIDONE AND THE CORRESPONDING THIONES SCHERING CORPORATION (US) 1990-08-29 EP claimed
EP-0228416-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES SCHERING CORPORATION (US) 1990-03-21 EP claimed
EP-0127135-A2 Fused tricyclic derivatives of naphthyridinone and pyridone and the corresponding thiones SCHERING CORPORATION (US) 1984-12-05 EP claimed
EP-0127135-B1 FUSED TRICYCLIC DERIVATIVES OF NAPHTHYRIDINONE AND PYRIDONE AND THE CORRESPONDING THIONES SCHERING CORPORATION (US) 1990-08-29 EP disclosed
EP-0228416-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES SCHERING CORPORATION (US) 1990-03-21 EP disclosed
EP-0338010-A1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE. SCHERING CORP (US) 1989-10-25 EP disclosed
US-4801589-A QUINOLINE, NAPHTHYRIDINE, AND PYRIDO-PYRAZINE DERIVATIVES SCHERING CORPORATION (US) 1989-01-31 US disclosed
WO-1988004172-A1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE SCHERING CORPORATION (US) 1988-06-16 WO disclosed
US-4740511-A ANTIALLERGENS, ANTIINFLAMMATORY, ANTIULCER AGENTS SCHERING CORPORATION (US) 1988-04-26 US disclosed
EP-0228416-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES. SCHERING CORP (US) 1987-07-15 EP disclosed
US-4680298-A Tricyclic anti-allergy and use as anti-inflammatory agents SCHERING CORPORATION (US) 1987-07-14 US disclosed
US-4680297-A Tricyclic positive inotropic agents SCHERING CORPORATION (US) 1987-07-14 US disclosed
WO-1986007537-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES SCHERING CORPORATION (US) 1986-12-31 WO disclosed
EP-0127135-A2 Fused tricyclic derivatives of naphthyridinone and pyridone and the corresponding thiones SCHERING CORPORATION (US) 1984-12-05 EP disclosed